PharmaJet Presents Needle-free Delivery of COVID-19 Vaccines and Beyond at World Vaccine Congress - Europe

Superior immunogenicity expands vaccine development with Needle-free delivery

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet^®, the maker of innovative, needle-free injection technology, announced that their latest partnerships and research results will be presented at the World Vaccine Congress - Europe on October 21. The presentation, entitled Needle-free Delivery: COVID-19 Vaccines and Beyond, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc.

The PharmaJet Needle-free Injection Systems (NFIS) are the first and only needle-free injection devices to pass World Health Organization pre-qualification standards (PQS) among other regulatory clearances. The devices are commercially validated for both 0.5mL Intramuscular/Subcutaneous (IM/SC) or 0.1mL Intradermal (ID) route. With PharmaJet NFIS delivery, the immunogenicity of nucleic acid vaccines across multiple indications was enhanced. Additionally, the improved patient and caregiver experience has resulted in increased vaccine compliance, safety, and comfort.

The systems have been used in multiple clinical studies in the vaccine development sector for COVID-19, Influenza, HPV, Zika, cancer, and others, and several are now entering commercialization phase. Most recently, the COVID-19 DNA vaccine developed by Zydus Cadila (ZYCOV-D) has received Emergency Use Authorization in India for individuals 12 years and up, delivered exclusively with the PharmaJet Tropis^® ID system. It is the first DNA vaccine to receive approval for use in humans. Other partners including BioNet Asia, GeneOne and DioSynVax/University of Cambridge are planning or continuing clinical trials.

“Our Needle-free injection technology has been validated as a preferred and effective delivery method, especially for nucleic acid vaccines and therapeutics,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “With the increasing amount of data showing improved vaccine immunogenicity¹, more partners are collaborating with PharmaJet as a pharmaceutical development and commercialization partner.”

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

¹ Data on file

About PharmaJet

PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis^® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis^® device for intradermal injections received authorization to apply the CE Mark in May 2016. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com. Follow us on LinkedIn.

Nancy Lillie
Nancy.Lillie@pharmajet.com
1-888-900-4321 Option 3